Alterity Therapeutics Files 6-K on Holding Change
Ticker: PRNAF · Form: 6-K · Filed: Oct 15, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: substantial-holding, 6-K, foreign-private-issuer
Related Tickers: ATHE
TL;DR
ALTERITY THERAPEUTICS (ATHE) filed a 6-K for change in substantial holding - watch for ownership shifts.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on October 15, 2025, reporting a change in substantial holding. This filing is incorporated by reference into several of the company's S-8 and F-3 registration statements. The company, formerly known as PRANA BIOTECHNOLOGY LTD, is based in Melbourne, Australia.
Why It Matters
This filing indicates a significant shift in ownership or control of Alterity Therapeutics, which could impact its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Changes in substantial holdings can signal shifts in investor confidence or strategic maneuvering, requiring closer monitoring.
Key Players & Entities
- ALTERITY THERAPEUTICS LTD (company) — Registrant
- PRANA BIOTECHNOLOGY LTD (company) — Former company name
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
FAQ
What specific change in substantial holding is reported in the 6-K filing?
The filing states 'Change in substantial holding' as Exhibit 99.1, but the details of the change are not provided in the summary text.
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer, and this specific filing reports a change in substantial holding and is incorporated by reference into registration statements.
When was Alterity Therapeutics Limited previously known by another name?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Which registration statements is this 6-K filing being incorporated into?
This 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
Where is Alterity Therapeutics Limited's principal executive office located?
The principal executive office of Alterity Therapeutics Limited is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-10-14 18:29:37
Filing Documents
- ea0261134-6k_alterity.htm (6-K) — 13KB
- ea026113401ex99-1_alterity.htm (EX-99.1) — 42KB
- 0001213900-25-098901.txt ( ) — 57KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 14, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Change in substantial holding 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 14, 2025 2